Following positive first-in-human Phase 1 single ascending dose and preliminary food-effect data with ART26.12, Artelo ...
GLP-1 drugs like Ozempic and Wegovy offer surprising benefits beyond weight loss, but also carry unexpected risks.
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for ...
Two new signings for the Providence women, an ACC commitment for the Bryant men and an official staff addition for the Rhode ...
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it ...
Life Sciences Revenue -- $1.6 million, decreasing 48.4%, with R2 segment revenue mainly impacted by declines in Glacial FX ...
Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026New data ...
Palatin Technologies, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-1.24333. Operator: Hello, ...
Nomura Diversified Income Fund outperformed its benchmark in 1Q26 despite market volatility from the Iran war. Read the full ...
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...
Good afternoon, and welcome to the presentation of Akastor's first quarter results. My name is Oyvind Paaske, CFO, and I'm joined today by our CEO, Karl Erik Kjelstad.
Koné project construction on-budget and ahead of schedule • Continued exploration success • Robust liquidity sources KONÉ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results